Invivyd doses first participants in Phase 1 trial of COVID-19 mAb candidate VYD2311

Invivyd, Inc.

Phase 1 trial (NCT06523153) of VYD2311 dosed first healthy volunteers; placebo-controlled, randomized.
Trial in Australia evaluating multiple dose levels, including intramuscular administration.
Preliminary data readouts expected Q4 2024; additional clinical readouts anticipated in 2025.
VYD2311 discovered via affinity maturation against recent SARS-CoV-2 variants; high in vitro potency.
Program builds on PEMGARDA (pemivibart), which received FDA EUA for COVID-19 PrEP in immunocompromised.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.